Implications of “no deal” Brexit for orphan and paediatric medicines

Joseph Elborn; Mark Flear; Damian Downey

Implications of “no deal” Brexit for orphan and paediatric medicines

Joseph Elborn, Mark Flear, Damian Downey

Research output: Other contribution

Abstract

In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.

Original language	English
Type	Blog entry
Media of output	BMJ Opinion blog
Publication status	Published - 19 Jul 2019

Publication series

Name	BMJ Blogs

Access to Document

https://blogs.bmj.com/bmj/2019/07/19/implications-of-no-deal-brexit-for-orphan-and-paediatric-medicines/Licence: Unspecified

Fingerprint Dive into the research topics of 'Implications of “no deal” Brexit for orphan and paediatric medicines'. Together they form a unique fingerprint.

Cite this

Elborn, J., Flear, M., & Downey, D. (2019, Jul 19). Implications of “no deal” Brexit for orphan and paediatric medicines. https://blogs.bmj.com/bmj/2019/07/19/implications-of-no-deal-brexit-for-orphan-and-paediatric-medicines/

@misc{74b086a3a6f849e3bbbb7015c25c61fe,

title = "Implications of “no deal” Brexit for orphan and paediatric medicines",

abstract = "In the event of a “no deal” Brexit some of the UK{\textquoteright}s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey. ",

author = "Joseph Elborn and Mark Flear and Damian Downey",

year = "2019",

month = jul,

day = "19",

language = "English",

series = "BMJ Blogs",

type = "Other",

}

TY - GEN

T1 - Implications of “no deal” Brexit for orphan and paediatric medicines

AU - Elborn, Joseph

AU - Flear, Mark

AU - Downey, Damian

PY - 2019/7/19

Y1 - 2019/7/19

N2 - In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.

AB - In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.

M3 - Other contribution

T3 - BMJ Blogs

ER -